NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Stock-Based Compensation

Schedule of stock-based compensation expense


		Three Months Ended September 30,						Nine Months Ended September 30,
		2023			2022			2023			2022
General and administrative		$	(178,915)		$	428,571		$	302,817		$	1,490,667
Research and development			(113,428)			82,041			(33,459)			613,818
Total		$	(292,343)		$	510,612		$	269,358		$	2,104,485

Schedule of stock options issued and outstanding


					Weighted-		Weighted-
					Average		Average		Total
					Exercise		Remaining		Aggregate
					Price Per		Contractual		Intrinsic
		Stock Options			Share		Life (in years)		Value
Outstanding at December 31, 2022		365,287		$	53.27
Granted		1,875			4.34
Exercised		(125,984)			0.02
Forfeited		(44,693)			66.51
Outstanding at September 30, 2023		196,485			83.93		4.81		$	—
Exercisable as of September 30, 2023		151,137		$	93.71		3.82		$	—

Schedule of key assumptions used to estimate the fair value of the stock options granted


		Nine Months Ended September 30,
		2023		2022
Expected term of options (years)		5.4 - 6.1		5.3 - 6.1
Expected common stock price volatility		82.3% - 85.2%		73.7% - 78.5%
Risk-free interest rate		3.5% - 4.0%		1.4% - 3.4%
Expected dividend yield		—		—

Schedule of changes in the outstanding restricted stock


					Weighted-
					Average Grant
		Restricted Stock			Date Fair Value
		Units			Price
Unvested as of December 31, 2022			—		$	—
Granted			19,823			4.00
Forfeited			(8,713)			—
Unvested as of September 30, 2023			11,110			4.00
Total unrecognized expense remaining		$	30,208
Weighted-average years expected to be recognized over			3.4